Idiopathic Pulmonary Fibrosis (IPF) Market by Route of Administration, Drug Class, and Geography - Forecast and Analysis 2023-2027

Published: Mar 2023

Pages: 164

SKU: IRTNTR75158

Snapshot

The idiopathic pulmonary fibrosis market size is estimated to grow at a CAGR of 6.68% between 2022 and 2027. The idiopathic pulmonary fibrosis market size is forecast to increase by USD 1,360.99 million. The growth of the market depends on several factors, including the increasing prevalence of respiratory diseases, the growing geriatric population, and an increase in the number of smokers.

This idiopathic pulmonary fibrosis market report extensively covers market segmentation by route of administration (oral and parenteral), drug class (systemic corticosteroids, immunosuppressants, tyrosine kinase inhibitors, and anti-fibrotic agents), and geography (North America, Europe, Asia, and Rest of World). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the size of the Idiopathic Pulmonary Fibrosis Market During the Forecast Period?

To learn more about this report, View Report Sample

Idiopathic Pulmonary Fibrosis Market: Key Drivers, Trends, Challenges, and Customer Landscape

The increasing prevalence of respiratory diseases is notably driving the market growth, although factors such as obstacles to reimbursement may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Idiopathic Pulmonary Fibrosis Market Driver

The increasing prevalence of respiratory diseases is notably driving the IPF market growth. IPF is a fatal lung condition that impairs thousands of people worldwide. Scarring of the lung tissue, which affects the ability of oxygen to be transported to the bloodstream, makes it difficult to breathe and lowers the quality of life. IPF prevalence has increased globally, which has caused researchers and healthcare professionals to express grave concern. All age groups and genders have seen an increase in IPF diagnoses in recent years, with people over 60 having a higher incidence of the disease. This is partly a result of global population aging and the consumption of unhealthful diets that fuel the growth of respiratory illnesses.

As IPF has a significant impact on the economy, the healthcare system as a whole, and the quality of life for affected people and their families, it is a major concern for medical professionals and researchers. Significant healthcare expenses, including hospitalization, medication, and other treatments, are related to the disease. IPF can also lead to disability, decreased productivity, and early retirement, which causes financial losses for both individuals and society. Thus, the increasing prevalence of respiratory diseases including IPF is expected to increase the adoption of IPF treatment, which will drive the growth of the global idiopathic pulmonary fibrosis (IPF) market during the forecast period.

Significant Idiopathic Pulmonary Fibrosis Market Trends

The emergence of new patterns of IPF is a primary trend in the IPF market growth. New IPF patterns are starting to appear in patients all over the world. Scarring of the lung tissue, which over time causes breathing problems and a decline in lung function, characterizes this chronic and progressive lung disease. The symptom exacerbation during viral infections like COVID-19 is one of the new patterns seen in IPF patients. Researchers have discovered that viral infections can exacerbate IPF patients' symptoms and hasten the course of the disease. This is especially concerning because COVID-19 has developed into a serious public health crisis on a global scale since 2020, and people with IPF are more likely to develop a severe illness or pass away from COVID-19.

The increased use of telehealth and remote monitoring among IPF patients is another new trend that has been noticed. Many medical practices switched to virtual visits and remote monitoring in response to the COVID-19 pandemic in order to lower the risk of exposure. Patients with IPF have found this to be a useful tool because it enables them to receive care in the convenience of their own homes while still receiving the required monitoring and treatment for the condition. Thus, such factors are expected to fuel the growth of the global idiopathic pulmonary fibrosis (IPF) market during the forecast period.

Major Idiopathic Pulmonary Fibrosis Market Challenge

Obstacles to reimbursement are major challenges impeding the IPF market growth. IPF is becoming more common everywhere, but the costs of treating it are not being covered adequately. Patients who suffer from respiratory disorders must use sophisticated medical equipment, such as nebulizers, aerosol inhalers, and oxygen systems, which are not covered by insurance policies. Services for home respiratory therapy are also excluded from reimbursement plans. As a result, respiratory therapists providing home care services encounter difficulties in facilitating access to medical facilities.

Due to the widespread nature of respiratory diseases and the potential need for ongoing intervention and monitoring, patients and their families may be subjected to a significant financial burden. Inhaled corticosteroids, which are used to stop respiratory attacks, frequently have high co-pays. Due to the high cost-sharing required, patients may be required to pay a percentage of the drug's price rather than a set co-pay. As a result, during the forecast period, the challenges related to IPF treatment or therapeutic reimbursements, which are typically very high, will have a negative impact on the idiopathic pulmonary fibrosis (IPF) market growth.

Key Idiopathic Pulmonary Fibrosis Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Idiopathic Pulmonary Fibrosis Market Customer Landscape

Who are the Major Idiopathic Pulmonary Fibrosis Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AstraZeneca Plc - The company engages in the discovery, development, manufacturing, marketing, and sale of pharmaceutical products. The key offerings of the company include idiopathic pulmonary fibrosis drugs such as saracatinib.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Idiopathic Pulmonary Fibrosis Market?

The market share growth by the oral segment will be significant during the forecast period. The oral route of administration of drugs for most indications, including IPF, is one of the easiest, most convenient, and non-invasive methods of delivering medication to the body. Since it can be administered at home and is the most patient-friendly, this route is preferred by the majority of patients. Various dosage forms for oral medications are available, including tablets, capsules, and liquid solutions that can be ingested.

Get a glance at the market contribution of various segments View the PDF Sample

The oral segment was valued at USD 1,340.00 million in 2017 and continued to grow until 2021. The benefit of taking medications orally is that one can easily self-administer them and change the dosage if necessary. Additionally, compared to other routes of administration, oral medications have a longer half-life, which means that their effects may last longer. Oral drug delivery also does away with the need for intravenous injections or inhalable drugs, which can be uncomfortable and challenging for some patients. Thus, the oral segment in the global idiopathic pulmonary fibrosis (IPF) market is expected to witness moderate growth during the forecast period.

Which are the Key Regions for the Idiopathic Pulmonary Fibrosis Market?

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Due to the rising prevalence of respiratory diseases like IPF, the regional IPF market is predicted to experience significant growth in the upcoming years. IPF pharmaceutical products have a significant market opportunity in North America due to the rising demand for IPF treatments and medications.

The aging population is one of the main causes of the high prevalence of IPF in North America. IPF mostly affects people over the age of 60, according to the American Lung Association, and due to the aging population in North America, it is predicted that more people will develop IPF during the forecast period. Another important factor in the growth of the rising prevalence of IPF is the high rate of smoking in North America. Smokers may be more likely to develop IPF because smoking harms the lungs. As a result, it is anticipated that IPF will be more common in nations with high smoking rates, such as the US, Canada, and Mexico. Thus, such factors are expected to drive the growth of the IPF market in North America during the forecast period.

Additionally, vendors in the area concentrate on creating new medications to treat IPF patients. For instance, Sandoz International GmbH (Sandoz International) announced the introduction of the first generic version of pirfenidone for IPF patients in the US in May 2022, expanding its line of respiratory medications. These medications are effective at reducing the rate at which patients with IPF lose lung function. Thus, such new innovations in drugs are expected to propel the growth of the regional IPF market during the forecast period.

The outbreak of COVID-19 negatively affected the regional market. However, following the large-scale implementation of COVID-19 vaccination drives, the lockdown restrictions in various countries were somewhat relaxed by 2021, which led to the resumption of business activities and operations in manufacturing units. Thus, such factors are expected to boost the growth of the market in North America during the forecast period.

Segment Overview

The idiopathic pulmonary fibrosis market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.

Route Of Administration Outlook (USD Million, 2017 - 2027)
- Oral
- Parenteral

Drug Class Outlook (USD Million, 2017 - 2027)
- Systemic corticosteroids
- Immunosuppressants
- Tyrosine kinase inhibitors
- Anti-fibrotic agents

Region Outlook (USD Million, 2017 - 2027)
- North America
  - The U.S.
  - Canada
- Europe
  - U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
  - Others
- Rest of World
  - Saudi Arabia
  - South Africa
  - Others

Parent Market Analysis

Technavio categorizes the global idiopathic pulmonary fibrosis market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent, the global pharmaceuticals market, covers products and companies engaged in research and development or production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.

Idiopathic Pulmonary Fibrosis Market Scope
Report Coverage	Details
Page number	164
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 6.68%
Market growth 2023-2027	USD 1,360.99 million
Market structure	Fragmented
YoY growth 2022-2023(%)	6.41
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 35%
Key countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Alembic Pharmaceuticals Ltd., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celix Pharma Ltd., Cipla Ltd., Daewoong Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., FibroGen Inc., Galapagos NV, Galecto Inc., GNI Group Ltd., Horizon Therapeutics Plc, Intas Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Liminal BioSciences Inc., MediciNova Inc., Merck and Co. Inc., Mission Therapeutics, Novartis AG, Shionogi and Co. Ltd., and United Therapeutics Corp.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View the PDF sample

What are the Key Data Covered in this Idiopathic Pulmonary Fibrosis Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the idiopathic pulmonary fibrosis market between 2023 and 2027
Precise estimation of the size of the idiopathic pulmonary fibrosis market size and its contribution to the market in focus on the parent market
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
A thorough analysis of the market’s competitive landscape and detailed information about vendors
Comprehensive analysis of factors that will challenge the growth of idiopathic pulmonary fibrosis market vendors

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global idiopathic pulmonary fibrosis market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global idiopathic pulmonary fibrosis market 2017 - 2021 ($ million)

4.2 Route of Administration Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Route of Administration Segment 2017 - 2021 ($ million)

4.3 Drug Class Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Drug Class Segment 2017 - 2021 ($ million)

4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Route of Administration

6.1 Market segments
- Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)

6.2 Comparison by Route of Administration
- Exhibit 32: Chart on Comparison by Route of Administration
- Exhibit 33: Data Table on Comparison by Route of Administration

6.3 Oral - Market size and forecast 2022-2027
- Exhibit 34: Chart on Oral - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Oral - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Oral - Year-over-year growth 2022-2027 (%)

6.4 Parenteral - Market size and forecast 2022-2027
- Exhibit 38: Chart on Parenteral - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Parenteral - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Parenteral - Year-over-year growth 2022-2027 (%)

6.5 Market opportunity by Route of Administration
- Exhibit 42: Market opportunity by Route of Administration ($ million)
- Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Drug Class

7.1 Market segments
- Exhibit 44: Chart on Drug Class - Market share 2022-2027 (%)
- Exhibit 45: Data Table on Drug Class - Market share 2022-2027 (%)

7.2 Comparison by Drug Class
- Exhibit 46: Chart on Comparison by Drug Class
- Exhibit 47: Data Table on Comparison by Drug Class

7.3 Systemic corticosteroids - Market size and forecast 2022-2027
- Exhibit 48: Chart on Systemic corticosteroids - Market size and forecast 2022-2027 ($ million)
- Exhibit 49: Data Table on Systemic corticosteroids - Market size and forecast 2022-2027 ($ million)
- Exhibit 50: Chart on Systemic corticosteroids - Year-over-year growth 2022-2027 (%)
- Exhibit 51: Data Table on Systemic corticosteroids - Year-over-year growth 2022-2027 (%)

7.4 Immunosuppressants - Market size and forecast 2022-2027
- Exhibit 52: Chart on Immunosuppressants - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Data Table on Immunosuppressants - Market size and forecast 2022-2027 ($ million)
- Exhibit 54: Chart on Immunosuppressants - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Immunosuppressants - Year-over-year growth 2022-2027 (%)

7.5 Tyrosine kinase inhibitors - Market size and forecast 2022-2027
- Exhibit 56: Chart on Tyrosine kinase inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Data Table on Tyrosine kinase inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 58: Chart on Tyrosine kinase inhibitors - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Tyrosine kinase inhibitors - Year-over-year growth 2022-2027 (%)

7.6 Anti-fibrotic agents - Market size and forecast 2022-2027
- Exhibit 60: Chart on Anti-fibrotic agents - Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Data Table on Anti-fibrotic agents - Market size and forecast 2022-2027 ($ million)
- Exhibit 62: Chart on Anti-fibrotic agents - Year-over-year growth 2022-2027 (%)
- Exhibit 63: Data Table on Anti-fibrotic agents - Year-over-year growth 2022-2027 (%)

7.7 Market opportunity by Drug Class
- Exhibit 64: Market opportunity by Drug Class ($ million)
- Exhibit 65: Data Table on Market opportunity by Drug Class ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 67: Chart on Market share by geography 2022-2027 (%)
- Exhibit 68: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison
- Exhibit 69: Chart on Geographic comparison
- Exhibit 70: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2022-2027
- Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.4 Europe - Market size and forecast 2022-2027
- Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027
- Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 US - Market size and forecast 2022-2027
- Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)

9.8 China - Market size and forecast 2022-2027
- Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%)

9.9 Japan - Market size and forecast 2022-2027
- Exhibit 95: Chart on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on Japan - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on Japan - Year-over-year growth 2022-2027 (%)

9.10 Germany - Market size and forecast 2022-2027
- Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.11 UK - Market size and forecast 2022-2027
- Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography
- Exhibit 107: Market opportunity by geography ($ million)
- Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 109: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 110: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 111: Overview on factors of disruption

11.4 Industry risks
- Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 113: Vendors covered

12.2 Market positioning of vendors
- Exhibit 114: Matrix on vendor position and classification

12.3 AstraZeneca Plc
- Exhibit 115: AstraZeneca Plc - Overview
- Exhibit 116: AstraZeneca Plc - Product / Service
- Exhibit 117: AstraZeneca Plc - Key news
- Exhibit 118: AstraZeneca Plc - Key offerings

12.4 Boehringer Ingelheim International GmbH
- Exhibit 119: Boehringer Ingelheim International GmbH - Overview
- Exhibit 120: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 121: Boehringer Ingelheim International GmbH - Key news
- Exhibit 122: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 123: Boehringer Ingelheim International GmbH - Segment focus

12.5 Bristol Myers Squibb Co.
- Exhibit 124: Bristol Myers Squibb Co. - Overview
- Exhibit 125: Bristol Myers Squibb Co. - Product / Service
- Exhibit 126: Bristol Myers Squibb Co. - Key news
- Exhibit 127: Bristol Myers Squibb Co. - Key offerings

12.6 Cipla Ltd.
- Exhibit 128: Cipla Ltd. - Overview
- Exhibit 129: Cipla Ltd. - Business segments
- Exhibit 130: Cipla Ltd. - Key news
- Exhibit 131: Cipla Ltd. - Key offerings
- Exhibit 132: Cipla Ltd. - Segment focus

12.7 F. Hoffmann La Roche Ltd.
- Exhibit 133: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 134: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 135: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 136: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 137: F. Hoffmann La Roche Ltd. - Segment focus

12.8 FibroGen Inc.
- Exhibit 138: FibroGen Inc. - Overview
- Exhibit 139: FibroGen Inc. - Product / Service
- Exhibit 140: FibroGen Inc. - Key offerings

12.9 Galapagos NV
- Exhibit 141: Galapagos NV - Overview
- Exhibit 142: Galapagos NV - Product / Service
- Exhibit 143: Galapagos NV - Key offerings

12.10 GNI Group Ltd.
- Exhibit 144: GNI Group Ltd. - Overview
- Exhibit 145: GNI Group Ltd. - Product / Service
- Exhibit 146: GNI Group Ltd. - Key offerings

12.11 Horizon Therapeutics Plc
- Exhibit 147: Horizon Therapeutics Plc - Overview
- Exhibit 148: Horizon Therapeutics Plc - Business segments
- Exhibit 149: Horizon Therapeutics Plc - Key news
- Exhibit 150: Horizon Therapeutics Plc - Key offerings
- Exhibit 151: Horizon Therapeutics Plc - Segment focus

12.12 Jubilant Pharmova Ltd.
- Exhibit 152: Jubilant Pharmova Ltd. - Overview
- Exhibit 153: Jubilant Pharmova Ltd. - Business segments
- Exhibit 154: Jubilant Pharmova Ltd. - Key news
- Exhibit 155: Jubilant Pharmova Ltd. - Key offerings
- Exhibit 156: Jubilant Pharmova Ltd. - Segment focus

12.13 Liminal BioSciences Inc.
- Exhibit 157: Liminal BioSciences Inc. - Overview
- Exhibit 158: Liminal BioSciences Inc. - Product / Service
- Exhibit 159: Liminal BioSciences Inc. - Key offerings

12.14 MediciNova Inc.
- Exhibit 160: MediciNova Inc. - Overview
- Exhibit 161: MediciNova Inc. - Product / Service
- Exhibit 162: MediciNova Inc. - Key offerings

12.15 Novartis AG
- Exhibit 163: Novartis AG - Overview
- Exhibit 164: Novartis AG - Business segments
- Exhibit 165: Novartis AG - Key offerings
- Exhibit 166: Novartis AG - Segment focus

12.16 Shionogi and Co. Ltd.
- Exhibit 167: Shionogi and Co. Ltd. - Overview
- Exhibit 168: Shionogi and Co. Ltd. - Product / Service
- Exhibit 169: Shionogi and Co. Ltd. - Key offerings

12.17 United Therapeutics Corp.
- Exhibit 170: United Therapeutics Corp. - Overview
- Exhibit 171: United Therapeutics Corp. - Product / Service
- Exhibit 172: United Therapeutics Corp. - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 173: Inclusions checklist
- Exhibit 174: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 175: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 176: Research methodology
- Exhibit 177: Validation techniques employed for market sizing
- Exhibit 178: Information sources

13.5 List of abbreviations
- Exhibit 179: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

idiopathic pulmonary fibrosis market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis